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Abstract
Polycystic Kidney Disease is an autosomal dominant disease common in some lines of Bull Terriers (BTPKD). The disease is
linked to the canine orthologue of human PKD1 gene, Pkd1, located on CFA06, but no disease-associated mutation has been
reported. This study sequenced genomic DNA from two Bull Terriers with BTPKD and two without the disease. A non-
synonymous G.A transition mutation in exon 29 of Pkd1 was identified. A TaqManH SNP Genotyping Assay was designed
and demonstrated the heterozygous detection of the mutation in 47 Bull Terriers with BTPKD, but not in 102 Bull Terriers
over one year of age and without BTPKD. This missense mutation replaces a glutamic acid residue with a lysine residue in
the predicted protein, Polycystin 1. This region of Polycystin 1 is highly conserved between species, and is located in the first
cytoplasmic loop of the predicted protein structure, close to the PLAT domain and the second transmembrane region. Thus,
this change could alter Polycystin 1 binding or localization. Analytic programs PolyPhen 2, Align GVGD and SIFT predict this
mutation to be pathogenic. Thus, BTPKD is associated with a missense mutation in Pkd1, and the application of this
mutation specific assay could reduce disease transmission by allowing diagnosis of disease in young animals prior to
breeding.
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Introduction
Bull Terrier Polycystic Kidney Disease (BTPKD) is an
autosomal dominant disease of English Bull Terriers which is
characterized by bilateral renal cysts [1,2] and leads to chronic
renal failure in middle to old age [1–3]. Cysts can be detected
using renal ultrasonography, the currently preferred method of
diagnosis for BTPKD. However, this method is expensive and
requires an experienced operator, and so a definitive diagnosis,
especially early in the disease course, is difficult in some cases [1].
Polycystic Kidney Disease (PKD) has been reported in many
species. However, English Bull Terriers, Persian cats, humans and
rats suffer from a very similar disease in terms of mode of
inheritance, age of onset, clinical signs and renal pathology [1,2,4–
6]. Genetic diseases which are similar across species may be caused
by mutations in orthologous genes [7].
While, the genetic cause of BTPKD is unknown. Studies in
humans have shown that 85–90% of Autosomal Dominant
Polycystic Kidney Disease (ADPKD) (OMIM ID: 173900) is caused
by mutations in PKD1 (Entrez Gene ID: 5310), with other cases
caused by mutations in PKD2 (Entrez Gene ID: 5311). Further,
Autosomal Dominant Polycystic Kidney Disease in Persian cats
(OMIA ID: 1451) is caused by a premature truncating mutation in
the feline Pkd1 orthologue (Entrez Gene ID: 100144606) [8].
In BTPKD, there is strong linkage between the BTPKD
phenotype and the region near the canine Pkd1 orthologue (Entrez
Gene ID: 606755) on CFA06 [9]. However, no disease-associated
mutations were identified in a previous study which sequenced
Pkd1 from cDNA made primarily from mRNA from peripheral
blood [10]. This may have occurred because the Pkd1 transcript is
present in very low copy numbers, and the mutation was not
detected. This is supported by the situation in humans and mice
where PKD1/pkd1 expression is greatest in fetal renal tissue, with
low levels present in adult tissue [11,12]. Alternately, the mutation
may cause mRNA instability, also making detection of mutations
difficult. Further, mutations leading to cryptic splicing, a deletion
in part of Pkd1, and chromosomal duplications and rearrange-
ments affecting Pkd1, were not excluded in the previous study. As
only coding regions and the 39 untranslated region (UTR) was
sequenced, mutations in intragenic non-coding sequence and the
59 UTR, non-exonic promoters, enhancers and other regulatory
sequences may also not have been detected.
Thus, mutation detection studies on stable genetic material,
genomic DNA (gDNA), would be useful to further investigate the
role of Pkd1 in BTPKD. This study aimed to screen gDNA from
English Bull Terriers of known BTPKD status, for possible
mutation/s associated with the disease. This study reports a
mutation in Pkd1 that is associated with BTPKD.
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Sequencing gDNA revealed a single non-synonymous G to A
transition (a change in DNA codon GAG to AAG) (NCBI Assay ID:
ss316885563) in cDNA nucleotide 9772 in predicted exon 29 of
the canine orthologue of Pkd1. This sequence change was present
in two BTPKD affected dogs but not in two unaffected dogs.
Affected dogs were heterozygous for this sequence change
(Figure 1).
Sequence analysis
Thirty-seven allelic variants, including nucleotide substitutions,
deletions and insertions, were identified in the 4 dogs whose pkd1
gDNA was sequenced in this study. These variants were in the
predicted 59 UTR, 46 exons and 44 introns of Pkd1 (Table 1). Of
these 37 variants, the 9772G.A variant was the most likely to be
disease-causing, as it was the only variant present in two BTPKD
affected dogs but not in two unaffected dogs. Thirty six other
variants were excluded from further analysis as they were less likely
to be pathogenic as either; 1) all dogs were homozygous for the
variant 2) all dogs were heterozygous for the variant 3) two normal
animals and one animal with BTPKD were homozygous for the
variant, and the other dog with BTPKD was heterozygous 4) one
normal animal was heterozygous for the variant and the other
dogs were homozygous for the wild-type allele 5) one dog with
BTPKD was heterozygous for the variant and the other dogs were
homozygous for the wild-type allele.
Sequencing data was consistent with the presence of 5 haplotye
blocks in the 4 dogs analyzed in this study (Table 1). Haplotype 1
was the background haplotype for the G.A mutation in BTPKD.
Haplotypes 1 and 2 were the most frequent in these 4 dogs.
Alignment of predicted Pkd1 exon 29 sequences in the dog, cat,
mouse and human showed 74% homology, with all species having
a G residue in the position of the BTPKD mutation or SNP
(Figure 2).
Genotyping
All 47 dogs with BTPKD had one copy of the A allele detected
by the TaqManH SNP Genotyping Assay for the BTPKD SNP.
None of the 102 dogs without BTPKD had this SNP. Genotyping
results were confirmed by sequencing a fragment containing the
SNP in an additional 10 Bull Terriers. Results were consistent,
with all five BTPKD affected dogs having the SNP but none of the
five BTPKD unaffected dogs.
Bioinformatic protein analysis
Bioinformatic protein analysis suggested the BTPKD-associated
mutation would change an amino acid in the predicted canine
Polycystin 1 protein (NCBI Accession Number: NP_001006651),
in a conserved region close to the predicted PLAT (Polycystin 1,
Lipoxygenase, Alpha-Toxin) domain and second transmembrane
region. The amino acid change, E3258K, would change
negatively charged glutamic acid to positively charged lysine.
Figure 2, shows these regions are conserved between different
mammalian species, with all species having a glutamic residue in
the BTPKD-associated mutation location. There was 84%
predicted homology between these species’ amino acid sequence
in the predicted first cytoplasmic loop of the protein, and 89% in
the region of the PLAT domain.
PolyPhen-2, Align GVGD and SIFT were used to predict the
effect of the amino acid substitution on the predicted encoded
protein (Table 2). PolyPhen-2 classified this mutation as ‘‘probably
damaging’’ with a 0.991/1 score. This score indicates the
mutation is predicted to affect protein function or structure with
a high degree of confidence.
Align GVGD classified the BTPKD substitution as a class C55
change, with a GV score of 0 and GD score of 56.87, and a risk
estimate of 2 to 2.5 for this change having a pathogenic effect on
the protein (Table 2). This class of sequence changes is the second
highest pathogenicity category, of out of the seven classes in the
Align GVGD classification system [13].
SIFT also predicted this substitution could affect the protein
function (score 0) with this assessment based on an alignment of
Polycystin 1 predicted sequences from the dog, cat, human,
Rhesus monkey, common chimpanzee, mouse, rat, horse, chicken,
and Japanese medaka fish (Japanese rice fish). Amino acid
substitutions with scores less than 0.05 are predicted to be
deleterious, and those with scores greater than or equal to 0.05 are
predicted to be tolerated.
Discussion
This study has found a nucleotide transition in predicted exon
29 of the canine Pkd1 orthologue that is highly likely to cause
BTPKD. In this study of 149 dogs, the mutation was only present
Figure 1. Chromatograms of the sequence in the region of the BTPKD-associated SNP in exon 29. (A) Chromatogram from an unaffected
animal showing the animal was homozygous for the wild-type G allele. (B) Chromatogram from an affected animal showing the animal was
heterozygous with G/A alleles. The changed DNA codon has been highlighted, and the nucleotide of interest is the first nucleotide of the codon.
doi:10.1371/journal.pone.0022455.g001
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Position/Haplotype
Nucleotide
Number
1
Nucleotide in
public databases
2
Dog 1
(affected)
Dog 2
(affected)
Dog 3
(unaffected)
Dog 4
(unaffected)
59 UTR ss316885484
3 171–192 22A 22A/31A 22A/31A 22A/31A 22A/31A
59 UTR ss316885498 720 T T/C C/C C/C C/C
59 UTR ss316885500 1326 G G/A A/A A/A A/A
Intron 4 ss316885502 234 G or T G/G G/G G/G G/G
Exon 7 ss316885504 122 G G/G G/G G/G G/T
Exon 7 ss316885506 206 G G/A G/A G/A G/A
Intron 7 ss316885508 110 11C 10C/11C 10C/11C 10C/11C 10C/11C
Intron 8 ss316885512 347 A or G A/G G/G G/G G/G
Intron 9 ss316885514 162 A or G A/G G/G G/G G/G
Intron 9 ss316885517 222 A or G A/G G/G G/G G/G
Intron 11 ss316885519 395 T or G T/T T/T T/T T/T
Exon 12 ss316885521 18 A or G A/G G/G G/G G/G
Intron 12 ss316885523 26–29 ACC or GGG GGG/GGG GGG/GGG GGG/GGG GGG/GGG
Intron 12 ss316885527 32 A or G G/G G/G G/G G/G
Intron 12 ss316885530 34–93 59 bp present Del/Del
4 Del/Del Del/Del Del/Del
Intron 14 ss316885534 171–184 11C or 13C 11C/13C 11C/13C 11C/13C 11C/13C
Exon 15 ss316885536 1235 C or G C/G C/C C/C C/C
Exon 15 ss316885539 1693 C or T C/C C/C C/C C/C
Intron 16 ss316885541 275 C or T C/T T/T T/T T/T
Exon 17 ss316885543 85–86 AA or GC GC/GC GC/GC GC/GC GC/GC
Intron 17 ss316885546 41 G or T G/G G/G G/G G/G
Exon 23 ss316885548 125 C C/T T/T T/T T/T
Exon 23 ss316885550 518 T C/T T/T T/T T/T
Intron 23 ss316885552 239 A A/G G/G G/G G/G
Exon 26 ss316885554 5 C or T C/C C/C C/C C/C
Intron 26 ss316885556 33 T or C T/T T/T T/T T/T
Intron 26 ss316885559 926 A or G A/G G/G G/G G/G
Intron 27 ss316885561 63–74 11C 10C/11C 10C/11C 10C/11C 10C/11C
Exon 29
5 ss316885563 42 G G/A G/A G/G G/G
Intron 30 ss316885565 335 C C/T T/T T/T T/T
Intron 30 ss316885567 597 C C/T T/T T/T T/T
Exon 31 ss316885569 28 G T/T T/T T/T T/T
Intron 37 ss316885571 204 C C/T T/T T/T T/T
Intron 41 ss316885573 19 6C 6C/7C 7C/7C 7C/7C 7C/7C
Intron 41 ss316885575 117 A or C C/C C/C C/C C/C
Intron 42 ss316885578 52 A A/G G/G G/G G/G
Haplotype
6 Hap 5/Hap 4
7 Hap 5/Hap 2 Hap 1/Hap 2 Hap 1/Hap 3
1The position of each variant as the number of nucleotide residues from the 59 end of the UTR, intron or exon.
2Expected nucleotide residues based on the sequence available in the public databases. These nucleotides are considered as normal alleles, as they are not likely to
cause the disease (refer to discussion). Where two nucleotides are recorded, there were two nucleotide variants reported for the relevant position in different
databases.
3NCBI Assay ID available at Single Nucleotide Polymorphism database (dbSNP).
4Del; Deletion of 59 bp.
5Mutation segregating with BTPKD. G is the wild type allele, and A the mutant allele.
6Predicted haplotypes observed in the dogs (the nucleotide in bold indicates the BTPKD SNP):
Haplotype 1: 31A-C-A-G-G-G-10C-G-G-G-T-G-GGG-G-Del-11C-C-C-T-G-C-G-T-T-G-C-T-G-10C-G-T-T-T-T-7C-C-G.
haplotype 2: 22A-C-A-G-G-A-11C-G-G-G-T-G-GGG-G-Del-13C-C-C-T-G-C-G-T-T-G-C-T-G-11C-G-T-T-T-T-7C-C-G.
Haplotype 3: 22A-C-A-G-T-A-11C-G-G-G-T-G-GGG-G-Del-13C-C-C-T-G-C-G-T-T-G-C-T-G-11C-G-T-T-T-T-7C-C-G.
Haplotype 4: 22A-T-G-G-G-A-11C-A-A-A-T-A-GGG-G-Del-13C-G-C-C-G-C-G-C-C-A-C-T-A-11C-G-C-C-T-C-6C-C-A.
Haplotype 5: 31A-C-A-G-G-G-10C-G-G-G-T-G-GGG-G-Del-11C-C-C-T-G-C-G-T-T-G-C-T-G-10C-A-T-T-T-T-7C-C-G.
7Hap; Haplotype.
doi:10.1371/journal.pone.0022455.t001
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protein bioinformatic evidence. All BTPKD dogs were heterozy-
gous for this sequence change, consistent with the findings in mice
and cats that animals homozygous for Pkd1 mutations die
embryonically [14–16].
In this study more than 27 kb of the canine Pkd1 orthologue was
sequenced, however some regions were excluded (Figure S1). Only
the 399 bp at the 39 end of intron 1 was sequenced, as the rest of the
p r e d i c t e di n t r o ni saG C - r i c ha r e ao fm o r et h a n1 4k b ,a n dt h e
sequence of the 59 splicing site was unknown at the time of the study.
Similarly, a region of 600 bp in predicted intron 30 was excluded
f r o ms e q u e n c i n ga st h es e q u e n c ew a su n k n o w na tt h et i m eo ft h e
study. Finally, 79 bp of sequence in 59 untranslated region extending
from nucleotides 903 to 981 could not be sequenced, possibly due to
the formation of hairpin or other secondary structures.
Thirty-six other nucleotide variants were found in canine Pkd1.
However, these variants were less likely to cause the disease, not only
due to inconsistencies with the mode of inheritance of BTPKD, but
also 19 of these variants were present in sequence in public databases
where, for example, NCBI sequence contained one allele and
Ensembl a second. These database sequences were considered likely
to be non-disease-associated variants as Pkd1 sequence in Ensembl is
from Boxer gDNA, a breed not reported with PKD. Similarly, the
sequence in NCBI is from Madin-Darby Canine Kidney Epithelial
Cells (MDCK) from a Cocker Spaniel, another breed not reported
with PKD. However, some of these variants could still play a role in
disease, and further studies could investigate this possibility.
The BTPKD mutation was not detected in a previous study
which sequenced Pkd1 from mRNA extracted from white blood
cells of BTPKD affected and normal animals [10]. The samples
used in the current study were from the same animals used in this
previous study, suggesting the mutant mRNA may be unstable and
degrade rapidly [17]. Expression analysis, using methods such as
quantitative PCR, to measure Polycystin 1 expression in affected
tissues would have been useful to investigate this. However,
suitable kidney tissue samples were not available for such analysis.
The exon 29 SNP that segregated with the BTPKD phenotype
is predicted to result in an amino acid change in the predicted
protein, Polycystin 1, replacing a negatively charged glutamic acid
residue with a positively charged lysine residue. Charge reversal
amino acid substitutions may have deleterious effects on proteins.
While the structure and domains of canine Polycystin 1 have not
been studied, the comparable amino acid is located within the first
cytoplasmic loop of human Polycystin 1 (NCBI Accession
Number: NP_001009944), 19 amino acids downstream from the
PLAT domain, and 31 amino acids upstream of the second
transmembrane region. These regions are highly conserved
between different mammal species.
The role of the intracellular and extracellular loops between the
transmembrane domains of the protein is still unknown, but
Polycystin 1 is known to bind to both focal adhesion and cell-cell
adhesion proteins, forming a Polycystin 1 complex [18–21]. Focal
adhesion sites are important in linking the extracellular matrix and
the actin cytoskeleton, regulating cell-matrix interactions, motility,
and signal transduction [21–25]. As the BTPKD predicted amino
acid changeislocated close tothe PLAT domainandtransmembrane
region, this change may alter cell-matrix interaction, mobility or
signal transduction of the protein. Further, being close to the
transmembrane region of the protein, the BTPKD predicted amino
acid change could alter localization/trafficking of the protein. Such
altered protein trafficking has been suggested to occur in mutant
Polycystin 1 in ADPKD and PKD mice models, as well as in other
inherited diseases in humans involving immunoglobulin-like proteins
[14,26,27]. Further studies are being conducted to investigate the
Figure 2. Nucleotide and amino acid sequence alignment in the region of the substitution. (A) Sequence of predicted exon 29 in mutant
and wild type canine Pkd1 has been aligned with that of cat, mouse and human. The mutation is highlighted in red. * Indicates conserved nucleotide
residues. (B) Polycystin 1 has been aligned in the mutant and wild type dog, cat, mouse and human. The protein has been aligned from the beginning
of the first transmembrane region (amino acid number 3081) to the end of the second transmembrane region (amino acid number 3309). The region
with amino acids in bold is the predicted first cytoplasmic loop. The amino acids in blue bold indicate the predicted PLAT domain within the first
cytoplasmic loop. The red bold represents the amino acid that predicted to have been changed in BTPKD. * Indicates conserved amino acid residues.
doi:10.1371/journal.pone.0022455.g002
Table 2. Prediction of pathogenicity of the predicted amino acid change in BTPKD as determined by PolyPhen-2, Align GVGD and
SIFT.
Prediction Tool Prediction data
PolyPhen-2 Score 0.991
Sensitivity 0.60
Specificity 0.96
Prediction Probably damaging substitution
1
Align GVGD GV 0.00
GD 56.87
Prediction Damaging substitution/Class C55
2
SIFT Sequences at position
3 10
Median sequence conservation 3.45
Score
4 0.00
Prediction Affects protein function
1Probably damaging, i.e., it is predicted to affect protein function or structure with a high degree of confidence.
2Substitution classification in Align GVGD: GD.=55+Tan(10)x(GV‘2.0)=.Class C55.
3Number of aligned sequences at the position of the substitution.
4SIFT scores range from 0 to 1. The amino acid substitution is predicted to be damaging if the score is ,=0.05, and tolerated if the score is .0.05.
doi:10.1371/journal.pone.0022455.t002
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Polycystin 1 by expressing both the wild type and the mutant proteins
in Madin-Darby Canine Kidney (MDCK) cells.
Identification of the mutation that is likely to cause BTPKD
supports the first cytoplasmic loop of Polycystin 1 being important
in the protein’s function. Little is known about this protein region
in humans or other species, and further studies on the effect of this
mutation on the structure and function of Polycystin 1 could
increase understanding about the protein.
Studies in ADPKD and PKD mice models have shown that
Polycystin 1 is present in high levels in fetal kidney tissues, but only
in low levels in adult tissue [11,12]. While cystogenesis does occur
in some cases in utero, a second somatic PKD1/Pkd1 mutation
appears to be required in a cell for a cyst to form from clonal
expansion of this cell [14,15,28,29], and as at least some humans
with ADPKD develop cysts in adulthood [30,31], it is likely that
the mutation continues to have a clinically significant effect
beyond the fetal stage. Other factors beside age of the patient are
also likely to play a role in cystogenesis including level of Polycystin
1 expression, and penetrance of pathogenic alleles [15,32–34].
The pathogenicity prediction tools, PolyPhen-2, Align GVGD
and SIFT also supported this amino acid substitution being
pathogenic. PolyPhen-2 is a software tool that predicts the possible
impact of amino acid substitutions on the structure and function of
proteins using biophysical and evolutionary comparisons. Align
GVGD is a program that combines the analysis of the biophysical
characteristics of amino acids and protein multiple sequence
alignments to predict the effect of mutations on the encoded
proteins. Finally, SIFT produces predictions about mutation
pathogenicity using amino acid sequences which are conserved
among different species, using multiple sequence alignments. The
prediction results obtained using these tools are in agreement with
each other, and suggest that this mutation is in a conserved region
of Polycystin 1 and has a high potential to affect the structure and
function of the protein.
Further support for the pathogenicity of the Pkd1 SNP found in
the BTPKD-affected dogs in this study comes form studies in other
species. In humans, mutations in PKD1 are responsible for up to
85–90% of ADPKD cases. Mutations are found anywhere in the
gene, and include nonsense, missense, frame shift, splicing,
deletions and insertions (http://www.hgmd.cf.ac.uk/ac/index.
php). Around 50% of the mutations found in PKD1 in humans
are classified as missense/nonsense mutations, and around half of
these are missense mutations. While the missense mutation
associated with BTPKD in this study has not been reported in
ADPKD, 10 missense mutations in PKD1 producing amino acid
changes in the first cytoplasmic loop of the protein have been
reported [34–40], of which six were shown to segregate with the
disease phenotype [35,38,40]. The closest of these missense
mutations to the BTPKD SNP is a R3247H mutation, five amino
acids upstream of the equivalent position of the BTPKD mutation
in human Polycystin 1. This mutation produces a conservative
substitution of arginine to histidine.
Three further disease-related glutamic acid to lysine changes
have been reported in ADPKD [34,36,38,40]. One of these E to K
changes in ADPKD in the PKD1 gene is an E3604K mutation that
has been classified as likely to be pathogenic [38]. Rossetti et al
(2001) have also reported that a putative missense mutation in
position 2771 segregated with the disease in four unrelated families
and was not observed in 230 normal cases, supporting its role in
the disease. Rossetti et al (2002) have also reported the same amino
acid change at amino acid position 1811 in ADPKD patients.
While, they were not able to test whether this change segregated
with the disease due to lack of samples [40], this amino acid
change has also been reported to be pathogenic in other proteins
as it changes their function [41,42]. Thus, mutations which are
similar to that in BTPKD are pathogenic and so also likely to be
disease causing in ADPKD.
Interestingly, feline PKD is due to C.A transversion in
predicted exon 29 of feline Pkd1, resulting in a stop codon at the
equivalent position of 3284 in human Polycystin 1 [8]. This
mutation is located in the equivalent region to the first
transmembrane domain of human Polycystin 1, only 32 amino
acids downstream of the BTPKD mutation. Feline PKD is another
similar disease to ADPKD and BTPKD, providing further support
for the BTPKD-associated mutation’s causative role in the disease.
Development of the TaqManH SNP Genotyping Assay is a
useful molecular genetic diagnostic test to diagnose BTPKD. This
test is favoured for detecting single nucleotide polymorphisms in
large-scale population mutation screening, as it is accurate,
sensitive, specific, rapid and cost effective [43]. Such a diagnostic
test would allow breeders to diagnose disease prior to breeding,
and thus prevent breeding of affected animals. It would also allow
the diagnosis of animals prior to development of clinical disease,
and so aid early treatment. Currently, ultrasonography is the
preferred method of diagnosis for BTPKD, as it is sensitive,
noninvasive, and quick, if performed by a highly skilled operator
[30,31]. However it is costly and the presence of cysts is
nonspecific for BTPKD. Ultrasonography may also not detect
disease in dogs with late enlargement of renal cysts [1]. In
addition, where less than 3 cysts are detected, or the cysts are
present only in one kidney, definitive diagnosis requires retesting,
pedigree inspection and possibly test mating. Moreover, variation
in the echogenicity of normal kidneys in Bull Terriers can also
make it difficult for ultrasonography to give a definitive diagnosis
[1]. Thus, this accurate, easy and inexpensive molecular genetic
diagnostic test will be useful to detect BTPKD at any age, from a
sample of blood, hair or a buccal swab.
All cases of reported BTPKD to date in Australia descend from
two affected half-siblings, making it very likely that there is only
one disease-causing mutation in the Australian Bull Terrier
population. Interestingly, these half-sibs were recently descended
from an imported animal, suggesting the disease may well be
international and due to this one mutation. Thus, a mutation-
based diagnostic test is desirable in this disease, as these tests are
accurate, sensitive, specific and inexpensive. They also avoid some
of the inaccuracies of a linkage-based diagnostic test, which detect
and analyze the presence of a genetic marker located near the
disease locus. Despite this, due to differences in the clinical
presentation, inheritance and pathology of PKD in other canine
breeds, it is unlikely the same mutation is the cause of PKD in the
Cairn Terrier [44] or West Highland White Terrier [45].
In summary, a G.A transition at nucleotide 9772 in cDNA in
predicted exon 29 of canine Pkd1 segregates with the BTPKD
phenotype and results in a predicted change of a glutamic acid to a
lysine residue at amino acid number 3258 of the predicted canine
Polycystin 1 protein. A TaqManH SNP Genotyping Assay has
been developed to identify this mutation.
Materials and Methods
Ethics Statement
The University of Queensland, Animal Ethics Committee, has
approved this study.
Selection of dogs and DNA extraction
Diagnosis of BTPKD was established using ultrasound as
described previously [1]. Unaffected Bull Terriers were over one
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Bull Terriers was extracted from peripheral blood using a salting-
out extraction method [46]. All affected dogs were descended from
two half-siblings. The Pkd1 orthologue was sequenced from gDNA
from four closely related animals; two affected with BTPKD and
two unaffected.
Amplification of Pkd1
Canine Pkd1 sequence was obtained from databases NCBI
(http://www.ncbi.nlm.nih.gov/), and Ensembl (http://ensembl.
genomics.org.cn/Canis_familiaris/Info/Index). At the time of the
study, the gene sequence was integrated into the canine genome
map with the exception of missing sequence from predicted
introns 1 and 30.
For PCR amplification canine Pkd1 was divided into 22
fragments 500–2000 bp in size (Table S1). Intron 1 was not
amplified as it was 14 kb, GC-rich and the 59 sequence was
unknown. However, 399 bp at the 39 end of this intron was
amplified to investigate 39 splicing sites for intron 1. Primers were
designed in predicted exonic sequence where possible using Primer
3 version 0.4.0 (http://frodo.wi.mit.edu), and analyzed using
OligoAnalyzer version 3.1 (http://www.idtdna.com/analyzer/
applications/oligoanalyzer/) (Table S1).
Fragments were amplified in polymerase chain reactions (PCR)s
containing 16 PCR Buffer containing 0.3 mM dNTPs and 1.5–
2.5 mM MgSO4 (QIAGEN, Hilden, Germany), 0.5–1 mM
forward and reverse primers, 0.5 U HotStar HiFidelity DNA
Polymerase (QIAGEN, Hilden, Germany), 0–16Q solution, and
10–40 ng DNA in a 10 ml reaction volume. Standard thermo-
cycling conditions were 95uC for 5 min, followed by 35 cycles of
94uC for 30 sec, 60uC for 1 min, and 72uC for 2 min; and one
cycle of 72uC for 10 mins (Table S1).
To confirm the size of the PCR products, samples were stained
using Blue/Orange 66loading dye (Progema, Madison, USA) and
electrophorezed (BIO-RAD, Hercules, USA) on a 1.5% agarose
gel (Progema, Madison, USA) using 16 TAE Buffer (Promega,
Madison, USA), 100006SYBRH Safe DNA gel stain (Invitrogen
Eugene, Oregon, USA) and size standard Lambda DNA/
EcoR+HindIII (Promega, Madison, USA), and visualized using
a transilluminator (BIO-RAD, Hercules, USA).
Sequencing of Pkd1
PCR products were purified using MinElute PCR Purification
Kit (QIAGEN, Hilden, Germany) and sequenced bidirectionally
using forward, reverse and internal sequencing primers. The
standard 20 ml sequencing reaction contained 10–100 ng purified
DNA, 1 ml Big Dye Terminator version 3.1 (Applied Biosystems,
Foster City, USA), 3.5 mL BigDye Sequencing Buffer (Applied
Biosystems, Foster City, USA) and 3.2 pmol sequencing primer.
Standard sequencing conditions were 94uC for 5 mins, followed
by 30 cycles of 94uC for 10 sec, 50uC for 30 sec, and 60uC for
2 mins (Table S1). Unincorporated dye terminators were removed
using an ethanol/EDTA/sodium acetate precipitation method,
according to the BigDyeH Terminator v3.1 Cycle Sequencing Kit
protocol (Applied Biosystems, Foster City, USA), the pellet diluted
and run on a 3130X/Genetic Analyzer (Applied Biosystems,
Foster City, USA).
Sequence analysis
Sequences were analyzed and assembled using ChromasPro,
version 1.33 (Technelysium Pty Ltd, Queensland, Australia) and
Sequencher, version 4.7 (Gene Codes Corporation, Ann Arbor,
USA). Consensus sequence was compared with those in public
databases NCBI http://blast.ncbi.nlm.nih.gov/Blast.cgi, and En-
sembl http://www.ensembl.org/Multi/blastview and from
BTPKD affected and unaffected animals.
Bioinformatic protein analysis
The translate tool http://au.expasy.org/tools/dna.html from the
ExPASy Proteomics Server was used to predict the change in amino
acid residue caused by the mutation. In order to predict the location
and effect of the amino acid change on the predicted canine
Polycystin 1 structure, it was compared to the well-annotated
human Polycystin 1. Thus, the predicted sequence of canine
Polycystin 1 in normal dogs and BTPKD dogs was compared with
that of Polycystin 1 from humans by using the following databases
and tools: UniProt http://www.uniprot.org from European Bioin-
formatics Institute (EMBL-EBI), Protein http://www.ncbi.nlm.nih.
gov/protein and Conserved Domain Database http://www.ncbi.
nlm.nih.gov/Structure/cdd/cdd.shtml from National Centre for
Biotechnology Information (NCBI). ClustalW2 http://www.ebi.ac.
uk/Tools/clustalw2/index.html from EMBL-EBI and COBALT
http://www.ncbi.nlm.nih.gov/tools/cobalt/ from NCBI were used
to align canine Polycystin 1 sequence with orthologous sequence in
other species. Tools including PolyPhen-2 http://genetics.bwh.
harvard.edu/pph2/dokuwiki/start, Align GVGD http://agvgd.
iarc.fr/agvgd_input.php and SIFT http://sift.jcvi.org/ were used
to predict the affect of the predicted altered amino acid on the
encoded protein.
Genotyping
The BTPKD-associated SNP was investigated using TaqManH
SNP Genotyping Assay (Applied Biosystems, Foster City, USA) in a
total of 47 affected and 102 unaffected Bull Terriers from a large
pedigree in which BTPKD was segregating. All the animals were more
than one year old at the time of the diagnosis to ensure the diagnosis
was correct [1]. A Custom TaqManHSNP Genotyping Assay (Applied
Biosystems, Foster City, USA) using specific PCR primers (sequence of
forward primer TCTGTCCGTCCGTCCCT, and reverse primer
GCCAGATGTGCTTGTCAAAGAAG), and probes (probe se-
quence to detect the wild type allele was TGGCCGAGCTGCAG
labelled with VICH fluorescent dye, and probe sequence to detect the
mutant allele was TGGCCAAGCTGCAG labelled with FAM
TM
fluorescent dye). Final concentrations of 16 TaqManH SNP
Genotyping Assay Mix, 16TaqManH Genotyping Master Mix, and
10 ng canine gDNA were mixed in a 25 ml total volume on a 96-well
plate, and the assay performed using a 7500 Real Time PCR System
(Applied Biosystems, Foster City, USA). The results were analyzed
using 7500 Software Version 2.0.4 (Applied Biosystems, Foster City,
USA). Fragment 19 was amplified and sequenced from gDNA from
five Bull Terriers with BTPKD and five Bull Terriers without BTPKD
(Table S1), to confirm SNP genotyping and sequencing results.
Supporting Information
Figure S1 Canine Pkd1 gene. This figure shows the canine
Pkd1 gene from the 59 untranslated region (UTR) to the 39
untranslated region. The solid boxes represent the 46 predicted
exons. The regions in 59 UTR, intron 1 and intron 30 marked
with clear ovals are regions of the gene that were not sequenced in
this study.
(TIFF)
Table S1 Conditions used for amplification and se-
quencing of Canine Pkd1 gene. This table shows sequences of
primers, and PCR amplification and sequencing reaction
conditions used for sequencing canine Pkd1 from genomic DNA.
(DOC)
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